A non‐retinol retinoic acid receptor‐γ (RAR‐γ/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A‐induced skin damage
British Journal of Pharmacology2022Vol. 179(19), pp. 4722–4737
Citations Over TimeTop 10% of 2022 papers
Xintong Dai, Jing Jin, Yan Jia, Kai Yang, Jingxia Han, Zhiyuan Zhang, Xiujuan Ding, Cheng Yao, Tao Sun, Caibin Zhu, Huijuan Liu
Abstract
Tectorignen is a non-retinol RAR-γ-selective agonist that can inhibit UV-induced skin damage and could be developed as a safe pharmaceutical component for the prevention of photoaging and skin inflammation.
Related Papers
- → Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety(2006)531 cited
- → Clinical Use of Topical Retinaldehyde on Photoaged Skin(1999)28 cited
- → Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams(1995)24 cited
- Topical retinoic acid (tretinoin) for photoaging: conceptions and misperceptions.(1996)
- → Marked improvement induced in photoaged skin of hairless mouse by ER36009, a novel RARγ‐specific retinoid, but not by ER35794, an RXR‐selective agonist(2006)7 cited